Concepedia

Comparison between vildagliptin and metformin to sustain reductions in HbA<sub>1c</sub> over 1 year in drug‐naïve patients with Type 2 diabetes

Anja Schweizer, A. Couturier, James E. Foley, S. Dejager

Diabetic Medicine · 2007 · 238 citations · 20 references

DOIFull text

Open access

Abstract

A clinically meaningful decrease in HbA(1c) that was sustained throughout a 1-year treatment in drug-naïve patients with Type 2 DM was seen with both metformin and vildagliptin monotherapy.

References

20

Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus&lt;SUBTITLE&gt;Progressive Requirement for Multiple Therapies (UKPDS 49)&lt;/SUBTITLE&gt;

Robert C. Turner · JAMA · 1999 · 2.4K citations

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

Christian Weyer, Clifton Bogardus, David M. Mott et al. · Journal of Clinical Investigation · 1999 · 1.9K citations · Full text

U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

Diabetes · 1995 · 1.9K citations

, , +16

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Bo Åhrén, Mona Landin‐Olsson, Per‐Anders Jansson et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 711 citations

, , +18

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Bo Åhrén, Ramón Gomis, Eberhard Standl et al. · Diabetes Care · 2004 · 485 citations · Full text